Title
Category
Credits
Event date
Cost
Scratching the Surface of BTK Inhibition for Chronic Spontaneous Urticaria: Beyond Skin Deep
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
BTK inhibitors have demonstrated great promise for addressing various treatment challenges for chronic urticaria patients by improving symptom control and more effective targeting of disease pathways.
JAK is Out of the Box: Leveling Up Care for Severe Alopecia Areata Across Patient Populations
  • LivDerm
  • TME
  • 0.75 AAPA Category I CME
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Severe alopecia areata (AA) causes a significant disease burden impacting multiple aspects of patients’ health, quality of life, and daily functioning. New treatment options, including Janus kinase (JAK) inhibitors, are becoming available, but diagnosis and management can be challenging, especially for pediatric patients and those with skin of color.
Trading Steroids for Targeted Topical Therapies: Clinical Pearls for Your AD, Psoriasis, and Seborrheic Dermatitis Patients
  • LivDerm
  • TME
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
$0.00
While corticosteroids hold a valuable place in the therapeutic toolkit for atopic dermatitis, psoriasis, seborrheic dermatitis, and similar conditions, targeted topical therapies may offer better options for individualized care. Non-steroidal targeted therapies allow for better efficacy, improved safety, long-term use, and treatment of sensitive regions of the skin. Health care professionals require expert guidance on clinical data for new and emerging targeted topical therapies and strategies for utilizing them to improve outcomes in adult and pediatric patients.